Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 1, 2010, Pages 36-42

  Roddy, Julianna V F ^a,b   Partridge, Suzanne M ^b,d   Rockey, Michelle L ^a,b   Pruemer, Jane M ^b   Guo, Jeff J ^b   Desai, Shaili J ^c   Safa, Malek M ^b,d  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adverse events; Arterial; Bevacizumab; Cancer patients; Colorectal cancer; Deep venous; Erythropoietin stimulating agents (ESAs); Thromboembolic events

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; CAPECITABINE; CLOPIDOGREL; ERYTHROPOIETIN; FLUOROURACIL; FOLINIC ACID; HORMONE; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; AORTA THROMBOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOEMBOLISM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 76749167037     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31819cccaf     Document Type: Article

References (28)

1. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779-1802.
2. Avastin-package insert-. Oceanside, CA. Genetech Bio-oncology, 2006.
3. Eskens FA, Vermeij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review. Eur J Cancer. 2006; 42:3127-3139.
4. Culy C. Bevacizumab: antiangiogenic cancer therapy. Drugs Today. 2005; 41:23-36.
5. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21: 60-65.
6. Ramaswamy B, Elias AD, Kelbick NT, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res. 2006;12:3124-3129. (Pubitemid 43837360)
7. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23:3502-3508.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
9. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan and bevacizumab-based therapy. J Clin Oncol. 2005;23:2574-2576.
10. Malka D, Van Den Eynde M, Boige V, et al. Splenic infarction and bevacizumab. Lancet. 2006;7:1038.
11. Roncalli J, Delord JP, Galinier M, et al. Bevacizumab in metastatic colorectal cancer: a left intracardiac thrombotic event. Ann Oncol. 2006;17:177-1178.
12. Donadon M, Vauthey J, Loyer EM, et al. Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevaizumab for colorectal liver metastases. World J Gastroenterol. 2006;12:6556-6558.
13. Rizzo D, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083-4107.
14. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007;43:258-270.
15. Lappin TR, Maxwell AP, Johnston PG. Warning flags for erythropoiesisstimulating agents and cancer-associated anemia. Oncologist. 2007;12:362-365.
16. Steensma DP, Loprinzi CL. Erythropoietin use in cancer patients: a matter of life or death? J Clin Oncol. 2005;23:5865-5868.
17. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA)-Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)-. FDA Alert, March 2007.
18. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708-714.
19. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst. 2005;97:489-498.
20. Westin SN, Skinner EN, Funk MJ, et al. Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer. Gynecol Oncol. 2007; 105:414-417.
21. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: ramdomised, doubleblind, placebo-controlled trial. Lancet. 2003;362:1255-1260.
22. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet. 2003;4:459-460. (Pubitemid 37009952)
23. Leyland-Jones B, Semiglazou V, Pavlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonamemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23:5960-5972.
24. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232-1239.
25. Phurrough S, Jacques L, Ciccanti M, et al. Memo for Erythropoiesis Stimulating Agents (ESAs) for Non-Renal Disease Indications: The Use of Erythropoiesis Stimulating Agents in Cancer and Related Neoplastic Conditions. Woodland, MD: Centers for Medicare and Medicaid Services; 2007:1-61.
26. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/ American Society of Hematology Clinical Practice Guideline Update. J Clin Oncol. 2008;26:1-18.
27. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoietin adminstration for the treatment of cancer-associated anemia. JAMA. 2008;299:914-924.
28. Kozloff M, Sugrue MM, Gelhorn A, et al. Serious arterial thromboembolic events in patients with metastatic colorectal cancer treated with bevacizumab: results from the BRiTE registry. J Clin Oncol. 2007;25:197s. Abstract 4136.